DOCSLIB.ORG

BJFM Issue 1 Formulary.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BJFM Issue 1 Formulary.Pdf Our regular review of pharmacotherapy FORMULARY runny nose, itchy nose and sneezing) than those given placebo or either fluticasone n First pre-prandial GLP-1 propionate or azelastine hydrochloride receptor agonist may offer alone.2 savings In a further study, Dymista achieved EMERGENT A new once-daily parenteral symptom relief up to 6 days faster than hypoglycaemic is now available in the fluticasone propionate monotherapy and THERAPIES UK for the management of uncontrolled 5 days faster than azelastine.3 type 2 diabetes in combination with oral Dymista was well tolerated, the most hypoglycaemics and/or insulin. commonly reported adverse effects being Lyxumia (lixisenatide) is the first n Novel hay fever formulation epistaxis, headache and dysgeusia.2 prandial glucagon-like peptide-1 (GLP- shows improved symptom According to GP and allergy expert 1) receptor agonist to be developed, control Dr Dermot Ryan, effective management and with a competitive price tag, may A new nasal spray offering fast and of AR remains a challenge for both represent a cost-effective option for the powerful symptomatic control of allergic healthcare professionals and patients. NHS. rhinitis (AR) has been launched in the UK “Non-adherence to treatment remains Lixisenatide has been shown to slow by Meda Pharmaceuticals. a significant issue, with patients unsure down the process of gastric emptying, Dymista®, a novel formulation of whether current first-line treatments are and thereby lower blood sugar after a fluticasone propionate and azelastine taking effect, based on their relatively meal. hydrochloride, is licensed for the slow onset of action and limited The approval of the new agent is based symptomatic treatment of moderate to relief of symptoms. The introduction on a comprehensive trial programme, severe seasonal and perennial AR where of new treatments such as Dymista which included 11 clinical studies and monotherapy with either intranasal that can address these issues is an more than 5,000 patients. Results from antihistamine or glucocorticoid is not important development in improving Phase 3 trials showed that a combination considered sufficient. the management of such a common but of lixisenatide with basal insulin, plus oral Around one in four people in the UK difficult to manage condition,” he said. antidiabetic agents such as metformin, suffer from perennial or seasonal AR. significantly reduced levels of HbA1c, Of these, over 50% have moderate to REFERENCES compared with placebo, in patients severe symptoms, and many remain 1. Pitman R, Paracha N et al. Episode pattern and with type 2 diabetes. It also reduced symptomatic in spite of receiving healthcare utilisation in patients with seasonal allergic rhinitis. Poster presented at EAACI 2012 postprandial fasting glucose compared treatment. A recent UK survey showed 2. Carr W et al. J Allergy Clin Immunol. with baseline. that most patients (70.5%) with moderate 2012;129(5):1282-89 3. Bachert C, Hampel F et al. MP29-02 and time to severe AR use multiple therapies in lyxuMIA AT A GLANCE§ an attempt to achieve symptom control, to response in the treatment of seasonal allergic rhinitis compared to marketed antihistamine and Active components although there is limited evidence to corticosteroid nasal sprays. Poster presented at Lixisenatide (10µg or 20µg) support this practice.1 the 30th Congress of the European Academy of solution The efficacy and safety of Dymista Allergy and Clinical Immunology (EAACI) 2011 Indication(s)* has been documented in several studies Adults with uncontrolled type 2 involving over 4000 patients, 1400 of DYMISTA AT A GLANCE§ diabetes, in combination with oral which received the new formulation. Active components hypoglycaemic agent A meta-analysis of three trials involving Azelastine hydrochloride (1mg) Dosing frequency almost 3400 patients with moderate-to- Fluticasone propionate (365µg) Starting dose: severe seasonal AR showed that those Indication(s)* 10µg o.d. for 14 days; receiving Dymista achieved significantly Moderate to severe seasonal or maintenance 20µg o.d. better reduction in total nasal symptom perennial allergic rhinitis Contraindications† score (comprising nasal congestion, Dosing frequency None† 1 spray per nostril twice daily Recommended minimum age § Please note: The information presented for Contraindications† 18 years the drugs featured is not comprehensive and None† Common adverse is taken from information provided by third Recommended minimum/ events (≥1/100)‡ party sources. For full information about any maximum age Hypoglycaemia, headache, drug featured, including special precautions, Min: 12 years Max: none gastrointestinal disturbance, please see the full summary of product characteristics using the link shown and/or Common adverse events (≥1/100) infections, dizziness, somnolence, consult the manufacturer. Epistaxis; headache, dysgeusia dyspepsia, back pain *See SmPC for full licensed indication Link for summary of product Link for summary of product †Hypersensitivity to active components and characteristics (SmPC) characteristics (SmPC) excipients is a contraindication for all drugs. www.medicines.org.uk/emc/ www.medicines.org.uk/emc/ ‡See SmPC for full details medicine/27579 medicine/27405 | July/August 2013 | 39 FORMULARY n New option for long-term among three recommendations on pain contraception technology management drugs to emerge from the annual meeting in June this year of the The first subcutaneously delivered appraisals European Medicines Agency (EMA)’s formulation of the long-acting Pharmacovigilance Risk Assessment reversible contraceptive (LARC) Committee (PRAC). medroxyprogesterone acetate (MPA) has n Dapagliflozin (Forxiga) The recommendations regarding been launched in the UK. Sayana Press NICE has published a final appraisal codeine seek to ensure that such is injected into the thigh or abdomen determination (FAD) recommending medicines, which have been associated every 13 weeks using a prefilled device the use of the novel once-daily oral with respiratory depression, are used only (Uniject®). hypoglycaemic dapagliflozin as a in children for whom the benefits are MPA is a steroidal progestin, treatment option for adults with type 2 greater than the risks. They include: a synthetic variant of the human diabetes. Codeine-containing medicines should hormone progesterone, which prevents The guidance supports the use only be used to treat acute to moderate ovulation and provides contraception of dapagliflozin as dual therapy in pain in children above 12 years of age for 13 weeks (+/- 1 week). In the two combination with metformin, and that cannot be relieved by other simple phase 3 clinical studies of 1787 women, in combination with insulin with or analgesics. no pregnancies were reported with without other oral antidiabetic drugs. These medicines should not be used at subcutaneous MPA. In combination with metformin, all in patients aged below 18 years who Over half of the participants in the dapagliflozin is recommended for use undergo surgery for the removal of the studies experienced amenorrhea after 12 in place of a sulphonylurea (SU) for tonsils or adenoids to treat obstructive months, and over half of women did not patients in whom an SU is not tolerated sleep apnoea, as these patients are more report any significant weight changes or contraindicated, or those who are susceptible to respiratory problems. while taking subcutaneous MPA. at significant risk of hypoglycaemia The PRAC further advised that, as the In adolescents (12-18 years), use of or its consequences. The addition of risk of side effects with codeine may also Sayana Press is only indicated when other dapagliflozin to metformin may also be apply to adults, codeine should not be contraceptive methods are considered preferable to a thiazolidinedione if further used in people of any age who are known unsuitable or unacceptable. weight gain is a concern. to be ultra-rapid metabolisers, nor in Dapagliflozin is the first in a new class breastfeeding mothers. SAYANA AT A GLANCE§ of treatments known as SGLT2 inhibitors, The Committee also published Active component which work independently of insulin recommendations on two other analgesic medroxyprogesterone acetate with a mechanism of action that reduces agents prescribed commonly in primary (MPA) the amount of glucose reabsorbed in the care: Indication(s)* kidney. Long-term reversible female The efficacy and safety of dapagliflozin Diclofenac: the Committee warned that contraception has been investigated in a comprehensive the cardiovascular effects of this NSAID Dosing frequency clinical development programme when given systemically are similar to Single injection at 13 week intervals involving over 5500 patients with type 2 those of selective COX-2 inhibitors. This Main contraindications† diabetes. Data from these trials show that applies particularly when diclofenac is Pregnancy (known or suspected); it effectively lowers HbA1c and maintains used at a high dose (150mg daily) and breast or genital organ malignancy; glycaemic control in adults with type 2 for long-term treatment. vaginal bleeding; hepatic diabetes for two years. It also has the Flupirtine (oral and suppository impairment; metabolic bone disease; secondary benefit of weight loss sustained formulations) should only be used to thromboembolic/cerebrovascular for up to two years and is generally well treat acute (short-term) pain in adults disease tolerated. who cannot use other suitable pain Recommended minimum/ n See ‘What are the options
Load more

Recommended publications
  • A Comparison of Fluticasone Propionate, 1 Mg Daily, with Beclomethasone Dipropionate, 2 Mg Daily, in the Treatment of Severe Asthma
    Copyright ©ERS Joumals Ltd 1993 Eur Respir J , 1993, 6, Sn-884 European Respiratory Joumal Printed in UK - all rights reserved ISSN 0903 - 1936 A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma N.C. Bames*, G. Marone**, G.U. Di Maria***, S. Visser, I. Utama++, S.L. Payne+++, on behalf of an International Study Group A comparison of fluticasone propionate. 1 mg daily, with beclomethasone dipropionate, • The London Chest Hospital, London, 2 mg daily, in the treatment of severe asthma. N. C. Bames, G. Marone, G.U. Di Maria, UK. ** Servizio di Allergologia e S. Visser. l Utama, S.L Payne, on behalf of an International Study Group. @ERS Immunologia Clinica. I Clinica Medica Journals Ltd 1993. Universita, Napoli, Italy. *** lnstituto Malattie Respiratorie, Ospedale Tomaselli, ABSTRACT: We wanted w compare the efficacy and safety of fluticasone propi­ Catania, Sicily, Italy. onate, a new topically active inhaled corticosteroid, to that of high dose beclo­ + H.F. Verwoerd Hospital, Pretoria, South methasone dipropionate, in severe adult asthma. Africa. ++ St Laurentius Ziekenhius, 1 Patients currently receiving between 1.5-2.0 mg·day- of an inhaled corticoster­ CV Roermond, The Netherlands. +++ oid were treated for six weeks in a double-blind, randomized, parallel group study Glaxo Group Research Ltd, Greenford, with 1 mg·day-1 fluticasone propionate (n•82), or 2 mg·day·1 beclometbasone Middlesex, UK. dipropionate (n•72). Mean morning peak expirarory flow rates (PEFR) increased from 303 w 321 Correspondence: N.C. Bames l·min-1 with fluticasone propionate, and from 294 w 319 l·min·1 with beclometbasone The London Chest Hospital dipropionate.
    [Show full text]
  • Flonase Sensimist Allergy Relief (Fluticasone Furoate)
    Flonase® Sensimist™ Allergy Relief (fluticasone furoate) – Rx-to-OTC Approval • On February 8, 2017, GlaxoSmithKline Consumer Healthcare announced the launch of Flonase Sensimist Allergy Relief (fluticasone furoate) nasal spray, as an over the counter (OTC) treatment to temporarily relieve symptoms of hay fever or other upper respiratory allergies: nasal congestion; runny nose; sneezing; itchy nose; and itchy, watery eyes (in ages 12 years and older). — Flonase Sensimist Allergy Relief contains 27.5 mcg/spray of fluticasone furoate. — Flonase Sensimist Allergy Relief should not be used in children less than 2 years of age. • Previously, fluticasone furoate was only available by prescription as Veramyst®. Veramyst is no longer commercially available. • Fluticasone is also available OTC as brand (Flonase® Allergy Relief, Children’s Flonase® Allergy Relief) and generic products containing 50 mcg/spray of fluticasone propionate. — These products share the same indications as Flonase Sensimist Allergy Relief, but are not intended for children under 4 years of age. • Prescription fluticasone propionate nasal spray (50 mcg/spray) is available generically and indicated for the management of the nasal symptoms of perennial non-allergic rhinitis in adult and pediatric patients aged 4 years and older. • Warnings for Flonase Sensimist Allergy Relief state the following: — Do not use: in children under 2 years of age, to treat asthma, if there is an injury or surgery to the nose that is not fully healed, or if an allergic reaction to Flonase Sensimist Allergy Relief or any of its ingredients has occurred. — Ask a doctor prior to use if the patient has or had glaucoma or cataracts.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Uncertainty Reigns in Error Disclosure Debate
    74 Practice Trends S K I N & A L L E R G Y N E W S • August 2008 Uncertainty Reigns in Error Disclosure Debate B Y J A N E M . A N D E R S O N ington, Seattle, told attendees at the annual desire full disclosure of harmful errors, harmful to the patient,” Dr. Gallagher said. Contributing Writer meeting of the American College of Physi- while at the same time worrying that The University of Washington recently cians that physicians are unsure about what health care workers might hide them. In surveyed 4,000 physicians about commu- WA S H I N G T O N — Physicians generally to include when they disclose a medical er- disclosure, they want “an explicit state- nication with patients, colleagues, and believe that medical errors—especially ror. But he added that physicians are ac- ment that an error occurred,” details of health care institutions about errors. those that cause an adverse event—should tively debating the best way to proceed. what happened, and the implications for According to Dr. Gallagher, the survey be disclosed to patients, but there is dis- “Over the next 5 years, we’re going to see their health, he said. on error disclosure was sent to 2,000 physi- agreement about the level of detail that very exciting changes,” he said. “I think Physicians define errors more narrowly cians in Washington State and 2,000 Cana- should be provided, according to a physi- physicians as a profession will be leading than patients do. They agree in principle dian physicians.
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • FLONASE (Fluticasone Propionate) Nasal Spray Bacterial, Viral, Or Parasitic Infection; Ocular Herpes Simplex)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, These highlights do not include all the information needed to use contact dermatitis, rash) have been reported after administration of FLONASE safely and effectively. See full prescribing information for FLONASE nasal spray. Discontinue FLONASE nasal spray if such FLONASE. reactions occur. (5.3) • Potential worsening of infections (e.g., existing tuberculosis; fungal, FLONASE (fluticasone propionate) nasal spray bacterial, viral, or parasitic infection; ocular herpes simplex). Use with Initial U.S. Approval: 1994 caution in patients with these infections. More serious or even fatal course --------------------------- RECENT MAJOR CHANGES --------------------------- of chickenpox or measles can occur in susceptible patients. (5.4) • Hypercorticism and adrenal suppression may occur with very high Warnings and Precautions, Glaucoma and Cataracts (5.2) 1/2019 dosages or at the regular dosage in susceptible individuals. If such --------------------------- INDICATIONS AND USAGE ---------------------------- changes occur, discontinue FLONASE nasal spray slowly. (5.5) FLONASE nasal spray is a corticosteroid indicated for the management of the • Monitor growth of pediatric patients. (5.7) nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients ------------------------------ ADVERSE REACTIONS ------------------------------ aged 4 years and older. (1) The most common adverse reactions (>3%) are headache, pharyngitis, ----------------------- DOSAGE AND ADMINISTRATION ----------------------- epistaxis, nasal burning/nasal irritation, nausea/vomiting, asthma symptoms, For intranasal use only. Recommended starting dosages: and cough. (6.1) • Adults: 2 sprays per nostril once daily (200 mcg per day). (2.1) To report SUSPECTED ADVERSE REACTIONS, contact • Adolescents and children aged 4 years and older: 1 spray per nostril once GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or daily (100 mcg per day).
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Single Ingredient Nasal Corticosteroids Beclomethasone dipropionate (Qnasl) Beclomethasone dipropionate monohydrate (Beconase AQ) Budesonide (Rhinocort) Ciclesonide (Omnaris, Zetonna) Flunisolide (Generic) Fluticasone Furoate (Flonase Sensimist) Fluticasone Propionate (Flonase, Xhance) Mometasone Furoate (Nasonex) Triamcinolone Acetonide (Nasacort) AHFS Classification: 52.08.08 Corticosteroids (EENT) Final Report February 2018 Review prepared by: Valerie Gonzales, Pharm.D., Clinical Pharmacist Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Vicki Frydrych, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor Joanne LaFleur, Pharm.D., MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved Contents Abbreviations ................................................................................................................................................ 2 Executive Summary ....................................................................................................................................... 3 Introduction .................................................................................................................................................. 5 Table 1. Nasal corticosteroid products .............................................................................................
    [Show full text]
  • Version 10 February 2012
    CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Zoreeda 25 Mikrogramm/125 Mikrogramm pro Dosis - Druckgasinhalation, Suspension Zoreeda 25 Mikrogramm/250 Mikrogramm pro Dosis - Druckgasinhalation, Suspension Fluticasone propionate, Salmeterol xinafoate Date: 11.05.2015 This module reflects the scientific discussion for the approval of Salmeterol plus Fluticason Propionat momaja 25 Mikrogramm/250 Mikrogramm Druckgasinhalator, Suspension and Salmeterol plus Fluticason-propionat momaja 25 Mikrogramm/125 Mikrogramm Druckgasinhalator, Suspension. The procedure was finalised at 04.08.2014. For information on changes after this date please refer to the module ‘Update’. 1/26 I. INTRODUCTION Based on the review of the quality, safety and efficacy data, the Member States have granted a marketing authorisation for Zoreeda 25 Mikrogramm/125 Mikrogramm pro Dosis - Druckgasinhalation, Suspension and Zoreeda 25 Mikrogramm/250 Mikrogramm pro Dosis - Druckgasinhalation, from Cipla Europe NV. The product is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta-2-agonist. A comprehensive description of the indications and posology is given in the SmPC. The marketing authorisation has been granted pursuant to Article 10(3)of Directive 2001/83/EC. Fluticasone propionate is a glucocorticoid anti-asthmatic inhalant (anti-inflammatory). Salmeterol xinafoate is a selective beta-2-adrenoceptor agonist (bronchodilator). II. QUALITY ASPECTS II.1 Introduction Salmeterol xinafoate and fluticasone propionate pressurised inhalation suspension comprises an aluminium canister with a suitable metering valve and a plastic actuator with dose indicator and fitted with dustcap in pouch with a silica gel bag.
    [Show full text]
  • TITLE: Fluticasone Furoate Versus Fluticasone Propionate for Seasonal Allergic Rhinitis: a Review of the Clinical and Cost-Effectiveness
    TITLE: Fluticasone Furoate versus Fluticasone Propionate for Seasonal Allergic Rhinitis: A Review of the Clinical and Cost-Effectiveness DATE: 13 June 2011 CONTEXT AND POLICY ISSUES: Seasonal allergic rhinitis is a common disorder with an US prevalence of about 10-30% in adults and 40% in children, affecting close to 60 million people.1,2 The Canadian Allergy, Asthma and Immunology Foundation estimates that 20-25% of Canadians have allergic rhinitis.3 In addition to allergen avoidance and immunotherapy, antihistamines and corticosteroids nasal spray are used to control nasal and ocular symptoms.4,5 Fluticasone furoate nasal spray (Avamys™ by GlaxoSmythKline Inc.) was approved by Health Canada in August 2007 for the treatment of seasonal allergic rhinitis.6 The efficacy of fluticasone furoate nasal spray for the treatment of nasal and ocular symptoms of allergic rhinitis was shown in a recent systematic review,7 as well as in randomized, double-blind, placebo- controlled studies.8,9 Fluticasone furoate nasal spray was not associated with hypothalamic- pituitary-adrenal axis suppression as shown in a randomized, double blind, placebo- and active- controlled (prednisone) study.10 To help in the consideration of formulary coverage of fluticasone furoate (Avamys™) for seasonal allergic rhinitis, this report compares the clinical and cost-effectiveness of fluticasone furoate with fluticasone propionate for the treatment of seasonal allergic rhinitis. RESEARCH QUESTIONS: 1) What is the clinical effectiveness of fluticasone furoate for seasonal allergic rhinitis as compared to fluticasone propionate? 2) What is the cost-effectiveness of fluticasone furoate for seasonal allergic rhinitis as compared to fluticasone propionate? Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada.
    [Show full text]
  • Preferred Drug List
    Kansas State Employee ANALGESICS Second Generation cefprozil Health Plan NSAIDs cefuroxime axetil diclofenac sodium delayed-rel Preferred Drug List diflunisal Third Generation etodolac cefdinir 2021 ibuprofen cefixime (SUPRAX) meloxicam nabumetone Erythromycins/Macrolides naproxen sodium tabs azithromycin naproxen tabs clarithromycin oxaprozin clarithromycin ext-rel sulindac erythromycin delayed-rel erythromycin ethylsuccinate NSAIDs, COMBINATIONS erythromycin stearate diclofenac sodium delayed-rel/misoprostol fidaxomicin (DIFICID) Effective 04/01/2021 NSAIDs, TOPICAL Fluoroquinolones diclofenac sodium gel 1% ciprofloxacin For questions or additional information, diclofenac sodium soln levofloxacin access the State of Kansas website at moxifloxacin http://www.kdheks.gov/hcf/sehp or call COX-2 INHIBITORS Penicillins the Kansas State Employees Prescription celecoxib amoxicillin Drug Program at 1-800-294-6324. amoxicillin/clavulanate The Preferred Drug List is subject to change. GOUT amoxicillin/clavulanate ext-rel To locate covered prescriptions online, allopurinol ampicillin access the State of Kansas website at colchicine tabs dicloxacillin http://www.kdheks.gov/hcf/sehp for the probenecid penicillin VK most current drug list. colchicine (MITIGARE) Tetracyclines What is a Preferred Drug List? OPIOID ANALGESICS doxycycline hyclate A Preferred Drug List is a list of safe and buprenorphine transdermal minocycline cost-effective drugs, chosen by a committee codeine/acetaminophen tetracycline of physicians and pharmacists. Drug lists fentanyl
    [Show full text]
  • TRELEGY ELLIPTA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypercorticism and adrenal suppression may occur with very high These highlights do not include all the information needed to use dosages or at the regular dosage in susceptible individuals. If such TRELEGY ELLIPTA safely and effectively. See full prescribing changes occur, discontinue TRELEGY ELLIPTA slowly. (5.8) information for TRELEGY ELLIPTA. • If paradoxical bronchospasm occurs, discontinue TRELEGY ELLIPTA and institute alternative therapy. (5.10) TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol • Use with caution in patients with cardiovascular disorders because of inhalation powder), for oral inhalation use beta-adrenergic stimulation. (5.12) Initial U.S. Approval: 2017 • Assess for decrease in bone mineral density initially and periodically --------------------------- RECENT MAJOR CHANGES --------------------------- thereafter. (5.13) Indications and Usage, Maintenance Treatment of Asthma (1.2) 9/2020 • Glaucoma and cataracts may occur with long-term use of ICS. Worsening Dosage and Administration, Recommended Dosage for 9/2020 of narrow-angle glaucoma may occur. Use with caution in patients with Maintenance Treatment of Asthma (2.3) narrow-angle glaucoma and instruct patients to contact a healthcare Contraindications (4) 9/2020 provider immediately if symptoms occur. Consider referral to an Warnings and Precautions, Serious Asthma-Related Events – 9/2020 ophthalmologist in patients who develop ocular symptoms or use Hospitalizations, Intubations, Death (5.1) TRELEGY ELLIPTA long term. (5.14) Warnings and Precautions, Effect on Growth (5.18) 9/2020 • Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct --------------------------- INDICATIONS AND USAGE ---------------------------- patients to contact a healthcare provider immediately if symptoms occur.
    [Show full text]
  • Fluticasone Furoate, Umeclidinium and Vilanterol (Trelegy)
    pat hways Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) Evidence summary Published: 14 June 2018 nice.org.uk/guidance/es18 Key points The content of this evidence summary was up-to-date in June 2018. See summaries of product characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory status: Fluticasone furoate/umeclidinium/vilanterol (Trelegy, GlaxoSmithKline UK) received a European marketing authorisation in November 2017. This triple-therapy inhaler contains an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA). It is licensed for maintenance treatment of adults with moderate- to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA (summary of product characteristics). Overview This evidence summary discusses 2 randomised controlled trials (RCTs) looking at the safety and efficacy of fluticasone furoate/umeclidinium/vilanterol (an ICS/LAMA and LABA combination inhaler) in people with COPD who were symptomatic despite regular maintenance treatment and who either had a history, or were at risk, of exacerbations. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 54 Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18) Fluticasone furoate/umeclidinium/vilanterol (Trelegy) is licensed for maintenance treatment of adults with moderate-to severe COPD who are not adequately treated by a combination of an ICS and a LABA. Fluticasone furoate/umeclidinium/vilanterol has been shown to reduce the annual rate of moderate or severe exacerbations by 15% compared with fluticasone furoate/vilanterol.
    [Show full text]